89 related articles for article (PubMed ID: 25837689)
1. Establishment of pharmacophore and VolSurf models to predict the substrates of UDP-glucuronosyltransferase1A3.
Wu Z; Zhang X; Ma Z; Wu B
Xenobiotica; 2015; 45(8):653-62. PubMed ID: 25837689
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches.
Ako R; Dong D; Wu B
Xenobiotica; 2012 Sep; 42(9):891-900. PubMed ID: 22494439
[TBL] [Abstract][Full Text] [Related]
3. In silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the VolSurf approach.
Dong D; Wu B
J Pharm Sci; 2012 Sep; 101(9):3531-9. PubMed ID: 22388963
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.
Sorich MJ; Smith PA; McKinnon RA; Miners JO
Pharmacogenetics; 2002 Nov; 12(8):635-45. PubMed ID: 12439224
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
J Med Chem; 2003 Apr; 46(9):1617-26. PubMed ID: 12699380
[TBL] [Abstract][Full Text] [Related]
6. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3.
Green MD; King CD; Mojarrabi B; Mackenzie PI; Tephly TR
Drug Metab Dispos; 1998 Jun; 26(6):507-12. PubMed ID: 9616184
[TBL] [Abstract][Full Text] [Related]
7. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.
Sorich MJ; Miners JO; McKinnon RA; Smith PA
Mol Pharmacol; 2004 Feb; 65(2):301-8. PubMed ID: 14742671
[TBL] [Abstract][Full Text] [Related]
8. Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.
Dong D; Ako R; Hu M; Wu B
Xenobiotica; 2012 Aug; 42(8):808-20. PubMed ID: 22385482
[TBL] [Abstract][Full Text] [Related]
9. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
[TBL] [Abstract][Full Text] [Related]
10. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
11. In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):836-40. PubMed ID: 14678246
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.
Ekins S; Bravi G; Ring BJ; Gillespie TA; Gillespie JS; Vandenbranden M; Wrighton SA; Wikel JH
J Pharmacol Exp Ther; 1999 Jan; 288(1):21-9. PubMed ID: 9862748
[TBL] [Abstract][Full Text] [Related]
13. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms.
Sakaguchi K; Green M; Stock N; Reger TS; Zunic J; King C
Arch Biochem Biophys; 2004 Apr; 424(2):219-25. PubMed ID: 15047194
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids.
Erichsen TJ; Aehlen A; Ehmer U; Kalthoff S; Manns MP; Strassburg CP
J Hepatol; 2010 Apr; 52(4):570-8. PubMed ID: 20189675
[TBL] [Abstract][Full Text] [Related]
15. A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids.
Pritchard M; Fournel-Gigleux S; Siest G; Mackenzie P; Magdalou J
Mol Pharmacol; 1994 Jan; 45(1):42-50. PubMed ID: 8302279
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance.
Ekins S; Obach RS
J Pharmacol Exp Ther; 2000 Nov; 295(2):463-73. PubMed ID: 11046077
[TBL] [Abstract][Full Text] [Related]
17. Surface descriptors for protein-ligand affinity prediction.
Zamora I; Oprea T; Cruciani G; Pastor M; Ungell AL
J Med Chem; 2003 Jan; 46(1):25-33. PubMed ID: 12502357
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population.
Chen Y; Chen S; Li X; Wang X; Zeng S
Drug Metab Dispos; 2006 Sep; 34(9):1462-7. PubMed ID: 16738032
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
Thondorf I; Voigt V; Schäfer S; Gebauer S; Zebisch K; Laug L; Brandsch M
Bioorg Med Chem; 2011 Nov; 19(21):6409-18. PubMed ID: 21955456
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
